ISSCR News
The ISSCR Partners with Nuffield Council on Bioethics to Compile Global Horizon Scan on Stem Cell Research
The International Society for Stem Cell Research (ISSCR) today announced a new partnership with the Nuffield Council on Bioethics (NCOB) to conduct an ambitious international horizon scan focused on the future of stem cell science and its ethical implications. The initiative will help signal and inform updates to the ISSCR Guidelines for Stem Cell Research and Clinical Translation and guide the Society’s broader public policy agenda.
The ISSCR and Novo Nordisk Foundation Collaborate to Host the Society’s 2028 Annual Meeting in Copenhagen
The International Society for Stem Cell Research (ISSCR) is proud to announce a collaboration with the Novo Nordisk Foundation to host the ISSCR Annual Meeting in Copenhagen, Denmark 27-30 June 2028.
The ISSCR Annual Meeting embodies the mission of both world-class organizations, supporting new frontiers in rigorous science to better human health. The conference is a revered global forum for stem cell science and regenerative medicine, uniting researchers, clinicians, industry leaders, and policy makers from more than 80 countries.
The ISSCR Responds to ICH’s Q1 Guideline on Stability Testing of Drug Substances and Drug Products
On 28 July, the ISSCR submitted a response to the International Council for Harmonisation’s (ICH) guideline on stability testing of drug substances and drug products. The ISSCR recommends adding specific examples to clarify appropriate applications of certain studies and incorporating considerations for diverse manufacturing models, particularly decentralized manufacturing, where products are administered immediately after production. The ISSCR also advises including guidance on pluripotent stem cell bank stability testing, referencing Tissue Engineered Products (TEP), and clarifying whether ATMP combined products are covered under the term “combination of a drug product with a medical device.”
To request the comments or learn more, contact Denise de Villa.
Alzheimer’s Disease Pathology and Potential Treatment Targets Identified in Brain Organoids
Alzheimer's disease (AD) is the most common neurodegenerative disease in older people, affecting up to 1 in 20 individuals aged 65 and above. In addition to environmental and lifestyle factors, genetic mutations can predispose an individual to AD and some rare forms of inherited “familial” AD (fAD) are caused by known genetic mutations, with these affected individuals developing AD with high probability and at relatively young age. In most cases, AD is diagnosed at advanced stages, but pathological alterations in brain cells may arise earlier in life, particularly in fAD which is known to manifest earlier in life.
To study early-life changes in fAD brain cells, researchers including Zhen-Ge Luo and colleagues from ShanghaiTech University, China, have leveraged stem cell-derived brain organoids, to model aspects of early human brain development and function in the laboratory.
The ISSCR and STEMCELL Technologies Partner to Launch Free, On-Demand Course on Standards for Human Stem Cell Use in Research
The International Society for Stem Cell Research (ISSCR) and STEMCELL Technologies are proud to announce a new partnership to produce a free, on-demand course for researchers seeking to incorporate the ISSCR Standards for Human Stem Cell Use in Research in their work.
Receive ISSCR Press Releases
Sign up be a part of ISSCR’s media list. Media Contact: Kym Kilbourne, Director of Media and Strategic Communications
Subscribe to ISSCR News.
Each month, ISSCR delivers scientific, policy, and community to your inbox .